NAD-boosting treatment shows no benefit for Parkinson's in trial
A yearlong trial involving 410 people with early Parkinson's found no clinical benefit from nicotinamide riboside. The findings were published in JAMA.
People with Parkinson's and those exploring NAD-boosting treatments may be interested; the evidence comes from a randomised trial.
- study
- nicotinamide riboside (NR)
- journal
- JAMA
- sample size
- 410
- population
- people with early Parkinson's disease
Taken from the source as published — check the details before acting on them.
Trial size and design
The study involved 410 participants with early Parkinson's disease and was conducted over a year.
Treatment tested
Nicotinamide riboside, a compound that increases NAD levels, was evaluated for its potential benefits.
Outcome
No clinical improvement was observed in participants taking the treatment compared to those who did not.
Common questions
What was the duration of the trial?
The trial lasted for one year.
Sources
- NAD-boosting treatment shows no Parkinson's benefit in yearlong trial MedicalXpress · medicalxpress.com
Headlines and links belong to the publishers listed above. The summary above is written by The Health Brief; see how this works.
